Comparative Pharmacology
Head-to-head clinical analysis: CARBINOXAMINE MALEATE versus DISOMER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBINOXAMINE MALEATE versus DISOMER.
CARBINOXAMINE MALEATE vs DISOMER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbinoxamine maleate is a first-generation antihistamine that competitively inhibits histamine at H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
Selective dopamine D2 receptor antagonist; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
Adults: 4-8 mg orally every 6-8 hours as needed. Maximum: 24 mg/day.
Adults: 1 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment, requiring dose adjustment in significant liver disease.
12–15 hours in adults with normal renal function; prolonged to 30–40 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion of metabolites and unchanged drug; ~60-70% of a dose is excreted in urine within 48 hours, with less than 5% as unchanged drug. Biliary/fecal elimination accounts for a minor fraction (<10%).
Renal: 80% as unchanged drug; biliary/fecal: 15% as metabolites; <5% unchanged in feces.
Category C
Category C
Antihistamine
Antihistamine